Danaos Corp. (DAC) reported a 71% dip in earnings for the second quarter due to an increase in refinancing-related professional fees. The containership operator’s stock fell 3% in the after-hours hurt by the company’s weak performance in the quarter.
Earnings for the quarter plunged 71% to $5.8 million or $0.05 per share. Adjusted earnings inched up 0.7% to $0.27 per share. The growth in the adjusted EPS was driven by a decline in operating expenses, an increase in other income and an operating performance improvement in equity investments.
Operating revenue slid by 0.4% to $113.5 million. The decline was due to the lower fleet utilization of its vessels despite re-chartering of certain of its vessels at higher rates.
Total contracted operating revenues were $1.6 billion as of June 30, 2018, with charters extending through 2028 and remaining average contracted charter duration of 5.3 years, weighted by aggregate contracted charter hire.
During the second quarter, Danaos had an average of 55 containerships. The company’s fleet utilization was 96.1%, down from 97.9% in the previous year quarter.
On August 10, the company consummated the agreement reached with certain lenders for the refinancing of about $2.2 billion of its debt maturing on December 31, 2018, lowering debt by about $551 million. Following this, the company’s capital structure has been strengthened and the maturities have been extended by more than 5 years until the end of 2023.
In connection with this debt refinancing, Danaos issued 99 million new shares of Danaos common stock to certain lenders, which represent 47.5% of the company’s outstanding common stock after giving effect to this issuance and diluting existing shareholders ratably.
Shares of Danaos ended Monday’s regular session up 4.84% at $1.62 on the NYSE. The stock had risen by 12% so far this year, while it slipped 3% in the past three months.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on